07:00 , May 12, 2014 |  BioCentury  |  Emerging Company Profile

Inotrem: Sepsis companion

Inotrem S.A. is betting that a companion diagnostic can help its TREM1 inhibitors tamp down inflammation in the right sepsis patients and improve its odds of success in an indication where the only approved drug...
07:00 , May 31, 2010 |  BioCentury  |  Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
07:00 , Mar 15, 2010 |  BC Week In Review  |  Company News

BioXell, Cosmo deal

Cosmo completed its previously announced acquisition of BioXell (see BioCentury, Nov. 23, 2009). BioXell S.p.A. (SIX:BXLN), Milan, Italy   Cosmo Pharmaceuticals S.p.A. (SIX:COPN), Lainate, Italy   Business: Neurology  ...
08:00 , Feb 22, 2010 |  BC Week In Review  |  Company News

BioXell, Lay Line, Roche deal

BioXell terminated its 2006 deal with Lay Line Genomics for exclusive rights to Lay Line's BXL1H5 (formerly MNAC13 ) technology. BioXell will return all rights to Lay Line for the humanized antibody against TrkA (...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Company News

BioXell, Cosmo deal

Cosmo completed its initial tender offer for BioXell, acquiring about 5.1 million shares (94.8%) at €5, or about €25.5 million ($34.9 million). The additional acceptance period for the offer begins on Feb. 15 and ends...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Company News

BioXell, Novo Nordisk deal

BioXell sold Novo Nordisk its triggering receptors expressed on myeloid cells (TREM) 1 program for €1 million ($1.4 million). The deal includes compounds targeting TREM1 and research tools. BioXell is being acquired by Cosmo Pharmaceuticals...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

BioXell management update

BioXell S.p.A. (SIX:BXLN), Milan, Italy   Business: Genitourinary, Musculoskeletal, Neurology   Departed: Laurence Skillern as CMO  ...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

BioXell, Cosmo deal

Specialty pharmaceutical company Cosmo will acquire BioXell in a cash, stock and put option transaction that the companies said values BioXell at CHF7.68 per share, or CHF41.3 million ($41 million) based on 5.4 million shares...
08:00 , Nov 23, 2009 |  BioCentury  |  Finance

Ebb & Flow

Movetis N.V. is looking to what could be the biggest European biotech IPO in the last two years, and if all the stars align, more than any new offering in Europe in more than five...
02:12 , Nov 19, 2009 |  BC Extra  |  Company News

Cosmo to acquire BioXell

Specialty pharmaceutical company Cosmo Pharmaceuticals S.p.A. (SIX:COPN) will acquire BioXell S.p.A. (SIX:BXLN) in a cash, stock and put option transaction that the companies said values BioXell at CHF7.68 per share, or CHF41.3 million ($41 million),...